GlassScriptPhysician profile
Aruna Perumal
NPI 1235579715
$1,850.92
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $214 · 2021: $221.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $357.57 | 2019-2020 | |
| Allergan, INC. | $223.27 | 2019-2020 | |
| Shire North American Group INC | $209.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $199.79 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $195.64 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.43 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $130.93 | 2019-2020 | |
| Neos Therapeutics, LP | $86.59 | 2019-2021 | |
| Abbvie INC. | $85.85 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $59.15 | 2019 | |
| Lundbeck LLC | $46.18 | 2019-2021 | |
| Tris Pharma INC | $39.06 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.88 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.62 | 2021 | |
| Noven Therapeutics, LLC | $15.78 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $13.58 | 2019 | |
| Adlon Therapeutics L.P. | $11.10 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Perumal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.